Agency / Source: Prodiance Corporation

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Prodiance and Xyntek Automate Spreadsheet Compliance for 21 CFR Part 11 - Prodiance and Xyntek strategic partnership to deliver spreadsheet control solutions to help global pharmaceutical and biotech organizations mitigate enterprise risk and improve compliance with 21 CFR Part 11 mandates
Prodiance and Xyntek Automate Spreadsheet Compliance for 21 CFR Part 11

 

PRZOOM - /newswire/ - San Ramon, CA, United States, 2009/06/15 - Prodiance and Xyntek strategic partnership to deliver spreadsheet control solutions to help global pharmaceutical and biotech organizations mitigate enterprise risk and improve compliance with 21 CFR Part 11 mandates.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Prodiance Corporation, a leading global provider of Governance, Risk and Compliance solutions, and Xyntek, a global leader in Consulting, Design and Build of IT and Automated Systems Solutions, and Compliance, today announced a strategic partnership to deliver spreadsheet control solutions to help global pharmaceutical and biotech organizations mitigate enterprise risk and improve compliance with 21 CFR Part 11 mandates.

The partnership enables Xyntek to provide best-of-breed IT consulting services including installation, training, project management, and advisory to pharmaceutical and biotech organizations deploying the Prodiance Enterprise Spreadsheet Manager system. Under the partnership, the companies will market and deliver the combined solution.

Based in the Philadelphia area, Xyntek is a recognized leader with over 23 years experience in delivering IT consulting services and solutions to help pharmaceutical and biotech organizations automate a variety of key business processes including drug discovery, research and development, pre-clinical and clinical operations, manufacturing, supply chain, and regulatory and GXP compliance.

"Uncontrolled and unmonitored spreadsheets, Access databases and other end-user computing (EUC) applications can expose life sciences organizations to significant non-compliance and operational risks," said Elliot Abreu, vice president at Xyntek. "A sustainable and automated solution to mitigate these risks requires the combination of domain expertise, best practices and value-added services, combined with market leading technology. Xyntek and Prodiance are now providing a combined, best-of-breed solution to address these needs."

"We’re very pleased to add Xyntek as a trusted channel partner," said Dr. Soheil Saadat, president and CEO of Prodiance Corporation. "The combination of their domain expertise and world class IT services will help accelerate the adoption of Prodiance Enterprise Spreadsheet Management technology within pharmaceutical and biotech organizations on a global basis."

For more information on the combined solution and partnership, Prodiance and Xyntek will be hosting an online seminar entitled 21 CFR Part 11 and Spreadsheets – Best Practices for Mitigating Risk and Improving Compliance on Thursday, June 25th, 2009.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Prodiance Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Prodiance and Xyntek Automate Spreadsheet Compliance for 21 CFR Part 11

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Eric Perry - Prodiance.com 
925-543-0054 eric.perry[.]prodiance.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Prodiance Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Prodiance Corporation / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  RightITnow, Inc.

Visit  BizJobs.com







 
  ©2005-2026 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today